| 1.26 0.09 (7.69%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.8 | 1-year : | 2.07 |
| Resists | First : | 1.54 | Second : | 1.77 |
| Pivot price | 1.27  |
|||
| Supports | First : | 1.16 | Second : | 0.97 |
| MAs | MA(5) : | 1.21 | MA(20) : | 1.35 |
| MA(100) : | 1.31 |
MA(250) : | 1.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.6 |
D(3) : | 6.1 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 1.88 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MYO ] has closed above bottom band by 46.4%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.26 - 1.27 | 1.27 - 1.28 |
| Low: | 1.17 - 1.18 | 1.18 - 1.19 |
| Close: | 1.24 - 1.26 | 1.26 - 1.28 |
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Tue, 13 Oct 2026
To pay taxes only, Myomo (MYO) officer plans to sell 3,133 shares as stock grants vest. - Stock Titan
Wed, 05 Aug 2026
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Wed, 29 Jul 2026
Myomo to Report Second Quarter 2026 Financial Results on August 5 - Business Wire
Thu, 25 Jun 2026
MYO Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 28 May 2026
Myomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain Stock - Yahoo Finance
Thu, 07 May 2026
Myomo, Inc. (MYO) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|